Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball, Gregor B. E. Jemec(Zealand University Hospital), Afsáneh Alavi(Mayo Clinic in Arizona), Z. Reguiaï(Polyclinique de Franche Comté), Alice B. Gottlieb(Icahn School of Medicine at Mount Sinai), Falk G. Bechara(Ruhr University Bochum), C. Paul, Evangelos J. Giamarellos Bourboulis(National and Kapodistrian University of Athens), A. Villani(Hospices Civils de Lyon), Andreas Schwinn, Franziska Ruëff, Larisha Pillay Ramaya, Adam Reich(Rzeszów University), Inês Lobo, Rodney Sinclair(Sinclair Dermatology), Thierry Passeron, Antonio Martorell(Hospital de Manises), Pedro Mendes‐Bastos, Georgios Kokolakis, Pierre‐André Bécherel, Magdalena B. Wozniak(Novartis (Ireland)), Angela Llobet Martinez(Novartis (Switzerland)), Xiaoling Wei(Novartis (China)), Lorenz Uhlmann(Novartis (Switzerland)), Anna Passera(Novartis (Switzerland)), Deborah Keefe(Novartis (United States)), Ruvie Martin(Novartis (United States)), Clarice Field(Novartis (Ireland)), Li Chen(Novartis (United States)), Marc Vandemeulebroecke(Novartis (Switzerland)), Shoba Ravichandran(Novartis (United States)), Elisa Muscianisi(Novartis (United States))
Cited by 296
Abstract
Related Papers
No related papers found
Powered by citation graph analysis